400 Pleasant Street
United States - Map
pSivida Corp. develops products to deliver drugs and biologics in the United States and the United Kingdom. The company develops its products based on its Durasert and Tethadur drug delivery technologies focusing on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company also provides Medidur, an injectable, sustained-release micro-insert designed to treat non-infectious uveitis affecting the posterior segment of the eye, which is in Phase III clinical trial.It has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.
|Dr. Paul Ashton B.Sc., Ph.D.,
Chief Exec. Officer, Pres and Exec. Director
|Mr. Leonard S. Ross ,
Principal Financial & Accounting Officer and VP of Fin.
|Ms. Lori H. Freedman Esq., B.A., J.D.,
VP of Corp. Affairs, Gen. Counsel and Company Sec.
|Mr. Marty Nazzaro ,
VP of Operations
|Mr. Brian Leedman B.Econ., M.B.A.,
VP of Investor Relations
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|